<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Apheresis</title><meta name="description" content="Apheresis (from Ancient Greek ἀφαίρεσις aphairesis, &quot;a taking away&quot;) is a medical technology in which the blood of a person is passed through an apparatus that separates one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy. One of the uses of apheresis is for collecting hematopoietic stem cells.[1] Depending on the substance that is being removed, different processes are employed in apheresis. If separation by density is required,..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Aphaeresis"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Apheresis"/><meta property="og:title" content="Apheresis"/><meta property="og:description" content="Apheresis (from Ancient Greek ἀφαίρεσις aphairesis, &quot;a taking away&quot;) is a medical technology in which the blood of a person is passed through an apparatus that separates one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy. One of the uses of apheresis is for collecting hematopoietic stem cells.[1] Depending on the substance that is being removed, different processes are employed in apheresis. If separation by density is required,..."/><meta property="og:url" content="https://grokipedia.com/page/Apheresis"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Apheresis"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:12.986Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Apheresis"/><meta name="twitter:description" content="Apheresis (from Ancient Greek ἀφαίρεσις aphairesis, &quot;a taking away&quot;) is a medical technology in which the blood of a person is passed through an apparatus that separates one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy. One of the uses of apheresis is for collecting hematopoietic stem cells.[1] Depending on the substance that is being removed, different processes are employed in apheresis. If separation by density is required,..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="e5a8f3e4ae7cc8c3db8f5d2086810de6-f0eb6587c10dc5c3-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=e5a8f3e4ae7cc8c3db8f5d2086810de6,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.17518847521450098,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#apheresis" class="transition-opacity hover:opacity-100 opacity-50">Apheresis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#method" class="transition-opacity hover:opacity-100 opacity-50">Method</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#continuous-flow-centrifugation" class="transition-opacity hover:opacity-100 opacity-50">Continuous flow centrifugation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#intermittent-flow-centrifugation" class="transition-opacity hover:opacity-100 opacity-50">Intermittent flow centrifugation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#centrifugation-variables" class="transition-opacity hover:opacity-100 opacity-50">Centrifugation variables</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#types" class="transition-opacity hover:opacity-100 opacity-50">Types</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#donation" class="transition-opacity hover:opacity-100 opacity-50">Donation</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#donor-safety" class="transition-opacity hover:opacity-100 opacity-50">Donor safety</a></li><li style="padding-left:3rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#kit-problems" class="transition-opacity hover:opacity-100 opacity-50">Kit problems</a></li><li style="padding-left:3rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#donor-selection" class="transition-opacity hover:opacity-100 opacity-50">Donor selection</a></li><li style="padding-left:3rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#plasticizer-exposure" class="transition-opacity hover:opacity-100 opacity-50">Plasticizer exposure</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#therapy" class="transition-opacity hover:opacity-100 opacity-50">Therapy</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#indications" class="transition-opacity hover:opacity-100 opacity-50">Indications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#asfa-categories" class="transition-opacity hover:opacity-100 opacity-50">ASFA categories</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diseases-and-disorders" class="transition-opacity hover:opacity-100 opacity-50">Diseases and disorders</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#fluid-replacement-during-apheresis" class="transition-opacity hover:opacity-100 opacity-50">Fluid replacement during apheresis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="apheresis" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Apheresis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Apheresis</strong> (from Ancient Greek ἀφαίρεσις <em>aphairesis</em>, &quot;a taking away&quot;) is a medical technology in which the blood of a person is passed through an apparatus that separates one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy.</span>
<span class="mb-4 block break-words text-[1em] leading-7">One of the uses of apheresis is for collecting hematopoietic stem cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="method" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Method<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Depending on the substance that is being removed, different processes are employed in apheresis. If separation by density is required, centrifugation is the most common method. Other methods involve absorption onto beads coated with an absorbent material<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_22abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> and filtration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The centrifugation method can be divided into two basic categories:<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_22qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h3 id="continuous-flow-centrifugation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Continuous flow centrifugation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Continuous flow centrifugation (CFC) historically required two venipunctures, as &quot;continuous&quot; means the blood is collected, spun, and returned simultaneously. Newer systems can operate with a single venipuncture by collecting blood in a vessel and alternating between drawing and returning it through the same needle, while the centrifuge continuously processes the blood held in the vessel.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> The main advantage of this system is the low extracorporeal volume used in the procedure, which may be advantageous in the elderly and for children.</span>
<h3 id="intermittent-flow-centrifugation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Intermittent flow centrifugation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Intermittent flow centrifugation (IFC) works in cycles, taking blood, spinning/processing it and then giving back the unused parts to the donor in a bolus. The main advantage is a single venipuncture site. It does require a larger extracorporeal volume and takes significantly longer to perform the procedure via IFC. As a result, it is less commonly used for therapeutic purposes and is more frequently found in Donation Center settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_24qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> To stop the blood from coagulating, an anticoagulant is automatically mixed with the blood as it is pumped from the body into the apheresis machine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h3 id="centrifugation-variables" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Centrifugation variables<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The centrifugation process itself has four variables that can be controlled to selectively remove desired components. The first is spin speed and bowl diameter, the second is &quot;sit time&quot; in the centrifuge, the third is solutes added, and the fourth is not as easily controllable: plasma volume and cellular content of the donor. The result in most cases is the classic sedimented blood sample with the red blood cells at the bottom, the buffy coat of platelets and white blood cells (lymphocytes, granulocytes, monocytes) in the middle and the plasma on top.</span>
<h2 id="types" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Types<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">There are numerous types of apheresis.</span>
<h3 id="donation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Donation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Blood taken from a healthy donor can be separated into its parts during <span class="inline text-[1em] leading-7">blood donation</span>, where the needed component is collected and the unharvested components are returned to the donor. <span class="inline text-[1em] leading-7">Fluid replacement</span> is usually not needed in this type of collection. In many countries, apheresis donors can donate platelets more often than those donating whole blood. There are several categories of component collections:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Plasmapheresis</span> – <span class="inline text-[1em] leading-7">blood plasma</span>. Plasmapheresis is useful in collecting FFP (fresh frozen plasma) of a particular ABO group. Commercial uses aside from FFP for this procedure include immunoglobulin products, plasma derivatives, and the collection of rare WBC and RBC antibodies.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Erythrocytapheresis</span> – <span class="inline text-[1em] leading-7">red blood cells</span>. Erythrocytapheresis is the separation of <span class="inline text-[1em] leading-7">erythrocytes</span> from whole blood. It is most commonly accomplished using the method of centrifugal sedimentation. The automated red blood cell collection procedure for donating erythrocytes is referred to as &#x27;Double Reds&#x27; or &#x27;Double Red Cell Apheresis.&#x27;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Plateletpheresis</span> (thrombapheresis, thrombocytapheresis) – <span class="inline text-[1em] leading-7">blood platelets</span>. Plateletpheresis is the collection of platelets by apheresis while returning the RBCs, WBCs, and component plasma. The yield is normally the equivalent of between six and ten random platelet concentrates. Quality control demands the platelets from apheresis be equal to or greater than 3.0 × 1011 in number and have a pH of equal to or greater than 6.2 in 90% of the products tested and must be used within five days.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Leukapheresis</span> – <span class="inline text-[1em] leading-7">leukocytes</span> (white blood cells). Leukopheresis is the removal of <span class="inline text-[1em] leading-7">PMNs</span>, basophils, eosinophils for transfusion into patients whose PMNs are ineffective or where traditional therapy has failed. There is limited data to suggest the benefit of <span class="inline text-[1em] leading-7">granulocyte transfusion</span>. The complications of this procedure are the difficulty in collection and short shelf life (24 hours at 20 to 24 °C). Since the &quot;buffy coat&quot; layer sits directly atop the RBC layer, HES, a sedimenting agent, is employed to improve yield while minimizing RBC collection. Quality control demands the resultant concentrate be 1.0 × 1010 granulocytes in 75% of the units tested and that the product be irradiated to avoid graft-versus-host disease (inactivate lymphocytes). Irradiation does not affect PMN function. Since there is usually a small amount of RBCs collected, ABO compatibility should be employed when feasible.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">Stem cell harvesting – <span class="inline text-[1em] leading-7">hematopoietic stem cells</span>. Circulating peripheral blood stem cells (PBSCs) are harvested to use in <span class="inline text-[1em] leading-7">peripheral stem cell transplantation</span> following administration of a mobilizing agent, such as granulocyte colony stimulating factor (G-CSF).</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">Lymphapheresis – <span class="inline text-[1em] leading-7">lymphocytes</span>. Lymphocytes are harvested to use in manufacture of <span class="inline text-[1em] leading-7">CAR T cell</span> products for T-cell-based immunotherapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dc8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
</li>
</ul>
<h4 id="donor-safety" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Donor safety<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">Single use kits – Apheresis is done using single-use kits, so there is no risk of infection from blood-contaminated tubing or centrifuge. Blood does not contact the device and during the separation, blood does not exit the kit.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2i9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">Reinfusion – At the end of the procedure, the remaining blood in the kit is given back to the donor with a process called &#x27;reinfusion&#x27;.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">Immune system effects – &quot;the immediate decreases in blood lymphocyte counts and serum immunoglobulin concentrations are of slight to moderate degree and are without known adverse effects. Less information is available regarding long-term alterations of the immune system&quot;.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2m9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
</li>
</ul>
<h5 id="kit-problems" class="group relative mb-1 mt-4 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Kit problems<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h5>
<span class="mb-4 block break-words text-[1em] leading-7">Two apheresis kit recalls were:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">Baxter Healthcare Corporation (2005), in which &quot;pinhole leaks were observed at the two-omega end of the umbilicus (multilumen tubing), causing a blood leak.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2iaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">Fenwal Incorporated (2007), in which there were &quot;two instances where the <span class="inline text-[1em] leading-7">anticoagulant citrate dextrose</span> (ACD) and saline lines were reversed in the assembly process. The reversed line connections may not be visually apparent in the monitor box, and could result in excessive ACD infusion and severe injury, including death, to the donor.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
</li>
</ul>
<h5 id="donor-selection" class="group relative mb-1 mt-4 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Donor selection<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h5>
<span class="mb-4 block break-words text-[1em] leading-7">People who do not use a drug that may prevent blood donation, who do not have the risk of the carrier of a disease, and who have suitable vascular structure may be apheresis donors. For apheresis platelet donation the donor&#x27;s pre platelet count should be above 150 x 10^9/L. For apheresis plasma donation, the donor&#x27;s total protein level should be greater than 60 g/L. For double red cell apheresis, donors of either gender require a minimum hemoglobin level of 14.0 g/dl.</span>
<h5 id="plasticizer-exposure" class="group relative mb-1 mt-4 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Plasticizer exposure<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h5>
<span class="mb-4 block break-words text-[1em] leading-7">Apheresis uses plastics and tubing, which come into contact with the blood. The plastics are made of <span class="inline text-[1em] leading-7">PVC</span> in addition to additives such as a <span class="inline text-[1em] leading-7">plasticizer</span>, often <span class="inline text-[1em] leading-7">DEHP</span>. DEHP leaches from the plastic into the blood, and people have begun to study the possible effects of this leached DEHP on donors as well as transfusion recipients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">&quot;current risk or preventive limit values for DEHP such as the RfD of the US EPA (20 μg/kg/day) and the TDI of the European Union (20–48 μg/kg/day) can be exceeded on the day of the plateletpheresis. ... Especially women in their reproductive age need to be protected from DEHP exposures exceeding the above mentioned preventive limit values.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">&quot;Commercial plateletpheresis disposables release considerable amounts of DEHP during the apheresis procedure, but the total dose of DEHP retained by the donor is within the normal range of DEHP exposure of the general population.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">&quot;Mean DEHP doses for both plateletpheresis techniques (18.1 and 32.3 μg/kg/day) were close to or exceeded the reference dose (RfD) of the US EPA and tolerable daily intake (TDI) value of the EU on the day of the apheresis. Therefore, margins of safety might be insufficient to protect especially young men and women in their reproductive age from effects on reproductivity. At present, discontinuous-flow devices should be preferred to avert conceivable health risks from plateletpheresis donors. Strategies to avoid DEHP exposure of donors during apheresis need to be developed.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">As of 2025, manufacturers like Baxter are transitioning to DEHP-free IV bags and tubing due to regulatory bans in states such as California and North Carolina, with full U.S. transition targeted by 2035.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
</li>
</ul>
<h3 id="therapy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Therapy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The various apheresis techniques may be used whenever the removed constituent is causing severe symptoms of disease. Generally, apheresis has to be performed fairly often, and is an invasive process. It is therefore only employed if other means to control a particular disease have failed, or the symptoms are of such a nature that waiting for medication to become effective would cause suffering or risk of complications. For autoimmune diseases in which apheresis is effective, it is used not as a standalone treatment, but rather in conjunction with therapies that reduce production of autoantibodies.</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Plasma exchange</span> – removal of the liquid portion of blood to remove harmful substances. The plasma is replaced with a replacement solution.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">LDL apheresis</span> – removal of <span class="inline text-[1em] leading-7">low density lipoprotein</span> in patients with <span class="inline text-[1em] leading-7">familial hypercholesterolemia</span>.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Lipoprotein(a)</span> (Lp(a)) apheresis – removal of elevated lipoprotein(a) in patients with cardiovascular risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e6eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Photopheresis</span> – used to treat <span class="inline text-[1em] leading-7">graft-versus-host disease</span>, <span class="inline text-[1em] leading-7">cutaneous T-cell lymphoma</span>, and <span class="inline text-[1em] leading-7">rejection in heart transplantation</span>.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7">Immunoadsorption with Staphylococcal <span class="inline text-[1em] leading-7">protein A</span>-agarose column – removal of allo- and autoantibodies (in autoimmune diseases, transplant rejection, hemophilia) by directing plasma through protein A-agarose columns. Protein A is a cell wall component produced by several strains of Staphylococcus aureus which binds to the Fc region of IgG.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Leukocytapheresis</span> – removal of malignant white blood cells in people with leukemia and very high white blood cell counts causing symptoms.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Erythrocytapheresis</span> – removal of erythrocytes (red blood cells) in people with <span class="inline text-[1em] leading-7">iron overload</span> as a result of <span class="inline text-[1em] leading-7">Hereditary haemochromatosis</span>. This process is also used for <span class="inline text-[1em] leading-7">exchange transfusion</span> in severe malaria, or in sickle cell patients with specific indications such as acute chest syndrome or stroke.</span>
</li>
<li class="text-[1em]">
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Thrombocytapheresis</span> – removal of platelets in people with symptoms from extreme elevations in platelet count such as those with <span class="inline text-[1em] leading-7">essential thrombocythemia</span> or <span class="inline text-[1em] leading-7">polycythemia vera</span>.</span>
</li>
</ul>
<h1 id="indications" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Indications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="asfa-categories" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">ASFA categories<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">In 2023,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> the <span class="inline text-[1em] leading-7">American Society for Apheresis</span> published the 9th Special Edition of <span class="inline text-[1em] leading-7">evidence based guidelines</span> for the practice of Apheresis Medicine. These guidelines are based upon a systematic review of available scientific literature. Clinical utility for a given disease is denoted by assignment of an <strong>ASFA Category</strong> (I – IV). The quality and strength of evidence are denoted by standard <span class="inline text-[1em] leading-7">GRADE</span> recommendations. ASFA Categories are defined as follows:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><strong>Category I</strong> for disorders where therapeutic apheresis is accepted as a first line treatment,</li>
<li class="text-[1em]"><strong>Category II</strong> for disorders where therapeutic apheresis is accepted as a second-line treatment,</li>
<li class="text-[1em]"><strong>Category III</strong> for disorders where the optimal role of therapeutic apheresis is not clearly established and</li>
<li class="text-[1em]"><strong>Category IV</strong> for disorders where therapeutic apheresis is considered ineffective or harmful.</li>
</ul>
<h2 id="diseases-and-disorders" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Diseases and disorders<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Only diseases (or mentioned special conditions thereof) with ASFA category I or II are displayed in <strong>bold</strong> , with category I being <em>underlined</em> in addition.</span>







































































































































































































































































































































































































































































































































































































































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Disease</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Special condition</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Apheresis type</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Category</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">ABO-incompatible</span><span class="text-[1em] leading-7"> </span><span class="inline text-[1em] leading-7">hematopoietic stem cell transplantation</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">ABO-incompatible</span><span class="text-[1em] leading-7"> solid </span><span class="inline text-[1em] leading-7">organ transplantation</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Kidney</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Heart ( &lt;40 months of age)</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Liver (</span><span class="inline text-[1em] leading-7">perioperative</span><span class="text-[1em] leading-7">)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Acute disseminated encephalomyelitis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7"><em>Acute inflammatory demyelinating polyneuropathy</em></span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Acute liver failure</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Age-related macular degeneration</span><span class="text-[1em] leading-7"> (AMD)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dry AMD</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Rheopheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Systemic </span><span class="inline text-[1em] leading-7">amyloidosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Amyotrophic lateral sclerosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Anti-neutrophil cytoplasmic antibody</span><span class="text-[1em] leading-7">-associated </span><span class="inline text-[1em] leading-7">rapidly progressive glomerulonephritis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dialysis dependence</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Diffuse alveolar </span><span class="inline text-[1em] leading-7">hemorrhage</span><span class="text-[1em] leading-7"> (DAH)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dialysis independence</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Goodpasture syndrome</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Dialysis independence</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Diffuse alveolar hemorrhage (DAH)</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dialysis dependence and no DAH</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Aplastic anemia</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">pure red cell aplasia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Aplastic anemia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><span class="inline text-[1em] leading-7">Pure red cell aplasia</span></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Autoimmune hemolytic anemia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Warm antibody autoimmune hemolytic anemia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><span class="inline text-[1em] leading-7">Cold agglutinin disease</span>, life-threatening</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Babesiosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Severe</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Erythrocytapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>High-risk population</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Burn</span><span class="text-[1em] leading-7"> with </span><span class="inline text-[1em] leading-7">circulatory shock</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Heart transplant</span><span class="text-[1em] leading-7"> with allograft</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Prophylaxis of rejection</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Photopheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Treatment of rejection</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Treatment of antibody-mediated rejection</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7"><em>Catastrophic antiphospholipid syndrome</em></span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Rasmussen&#x27;s encephalitis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">immunoadsorption</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7"><em>Chronic inflammatory demyelinating polyneuropathy</em></span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Coagulation factor</span><span class="text-[1em] leading-7"> inhibitors</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Immunoadsorption</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Cryoglobulinemia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Severe/symptomatic</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Secondary to<span class="inline text-[1em] leading-7">Hepatitis C</span></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Immunoadsorption</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Cutaneous T cell lymphoma</span><span class="text-[1em] leading-7">: </span><span class="inline text-[1em] leading-7">mycosis fungoides</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">Sézary disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Erythrodermic</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Photopheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Non-erythrodermic</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Dermatomyositis</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">polymyositis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Leukapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Dilated cardiomyopathy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">NYHA class</span><span class="text-[1em] leading-7"> II-IV</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Immunoadsorption</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Familial hypercholesterolemia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Homozygotes</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">LDL apheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Heterozygotes</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Homozygotes with small blood volume</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Focal segmental glomerulosclerosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Recurrent</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Graft-versus-host disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Skin</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Photopheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Non-skin</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Hemolytic disease of the fetus and newborn</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Before intrauterine transfusion availability</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Hereditary haemochromatosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Erythrocytapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Hemolytic–uremic syndrome</span><span class="text-[1em] leading-7"> (HUS)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Atypical HUS due to mutations in complement factor genes</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Atypical HUS due to<span class="inline text-[1em] leading-7">factor H</span> autoantibodies</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Typical HUS, or diarrhea-associated HUS</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Leukocytosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em><span class="inline text-[1em] leading-7">Leukostasis</span></em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Leukapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Prophylaxis of leukostasis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Hyperviscosity</span><span class="text-[1em] leading-7"> in </span><span class="inline text-[1em] leading-7">monoclonal gammopathy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Treatment of symptoms</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Prophylaxis in<span class="inline text-[1em] leading-7">rituximab</span></em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Immune thrombocytopenic purpura</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Immune complex</span><span class="text-[1em] leading-7">-type of </span><span class="inline text-[1em] leading-7">rapidly progressive glomerulonephritis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Inclusion body myositis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">leukapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Inflammatory bowel disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Leukapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Kidney transplantation</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Antibody-mediated rejection</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Desensitization in living donor in positive crossmatch due to donor specific HLA antibody</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">High </span><span class="inline text-[1em] leading-7">PRA</span><span class="text-[1em] leading-7"> and cadaveric donor</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Lambert–Eaton myasthenic syndrome</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Lung transplantation</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Allograft rejection</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Malaria</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Severe</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Erythrocytapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Multiple sclerosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Acute<span class="inline text-[1em] leading-7">inflammatory demyelinating diseases of the central nervous system</span>, unresponsive to steroids</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Chronic progressive</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Myasthenia gravis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Moderate to severe</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Pre-<span class="inline text-[1em] leading-7">thymectomy</span></em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Myeloma cast nephropathy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Nephrogenic systemic fibrosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Photopheresis</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Neuromyelitis optica</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Venoms</span><span class="text-[1em] leading-7">, </span><span class="inline text-[1em] leading-7">poisoning</span><span class="text-[1em] leading-7"> and </span><span class="inline text-[1em] leading-7">overdose</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><span class="inline text-[1em] leading-7">Mushroom poisoning</span></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Other</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Paraneoplastic syndrome</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Neurologic</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">immunoadsorption</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Pancreatitis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Secondary to </span><span class="inline text-[1em] leading-7">hypertriglyceridemia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Polyneuropathy</span><span class="text-[1em] leading-7"> due to </span><span class="inline text-[1em] leading-7">monoclonal gammopathy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>IgG, IgA or IgM</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Multiple myeloma</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IgG/IgA or IgM</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Immunoadsorption</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em><span class="inline text-[1em] leading-7">PANDAS</span> and <span class="inline text-[1em] leading-7">Sydenham&#x27;s chorea</span></em></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Pemphigus vulgaris</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Photopheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Refsum disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Polycythemia vera</span><span class="text-[1em] leading-7"> or </span><span class="inline text-[1em] leading-7">erythrocytosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Erythrocytapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">POEMS syndrome</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Post-transfusion purpura</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Psoriasis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Rheumatoid arthritis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Refractory</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Immunoadsorption</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Schizophrenia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Systemic scleroderma</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Photopheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Sepsis</span><span class="text-[1em] leading-7"> with </span><span class="inline text-[1em] leading-7">multi-organ failure</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Sickle cell disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Acute<span class="inline text-[1em] leading-7">stroke</span></em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Erythrocytapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><span class="inline text-[1em] leading-7">Acute chest syndrome</span></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Prophylaxis of stroke or transfusional<span class="inline text-[1em] leading-7">iron overload</span></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Multi-organ failure</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Stiff-person syndrome</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Systemic lupus erythematosus</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Severe, such as<span class="inline text-[1em] leading-7">cerebritis</span> or <span class="inline text-[1em] leading-7">diffuse alveolar hemorrhage</span></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Nephritis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Thrombocytosis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Symptomatic</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plateletpheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Prophylactic</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Thrombotic microangiopathy</span><span class="text-[1em] leading-7">, drug-associated</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em><span class="inline text-[1em] leading-7">Ticlopidine</span></em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Cyclosporine</span><br/><span class="inline text-[1em] leading-7">Tacrolimus</span><br/><span class="inline text-[1em] leading-7">Clopidogrel</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Gemcitabine</span><br/><span class="inline text-[1em] leading-7">Quinine</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Thrombotic microangiopathy</span><span class="text-[1em] leading-7">, </span><span class="inline text-[1em] leading-7">hematopoietic stem cell transplantation</span><span class="text-[1em] leading-7">-related</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7"><em>Thrombotic thrombocytopenic purpura</em></span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Thyroid storm</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Wilson&#x27;s disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong><em>Fulminant hepatic failure with hemolysis</em></strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Plasmapheresis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><em>I</em></td></tr></tbody></table></div>
<h1 id="fluid-replacement-during-apheresis" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Fluid replacement during apheresis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">When an apheresis system is used for therapy, the system removes typically 1 to 1.5 times the patient&#x27;s plasma volume (approximately 40-60 mL/kg body weight).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> That fluid must be replaced to maintain intravascular volume. The choice of replacement fluid varies by institution and indication. Crystalloids like normal saline are sometimes used but do not maintain oncotic pressure and are not routinely recommended as the sole replacement fluid due to risk of hypotension. Human serum albumin is commonly used but is costly. Routine use of fresh frozen plasma (FFP) is generally not appropriate because of risks including citrate toxicity (from the anticoagulant), ABO incompatibility, infection, and allergic reactions. However, FFP should be used in cases of thrombotic thrombocytopenic purpura or patients at high risk of bleeding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Katherine, Abel; American Academy of Professional Coders (2013). <em>Official CPC Certification Study Guide</em>. Delmar Cengage Learning. p. 128. <span class="inline text-[1em] leading-7">ISBN</span> 978-1-285-42799-7. <span class="inline text-[1em] leading-7">OCLC</span> <a href="https://search.worldcat.org/oclc/1073648099" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1073648099</a>.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Fuchs, Kornelius; Rummler, Silke; Ries, Wolfgang; Helmschrott, Matthias; Selbach, Jochen; Ernst, Friedlinde; Morath, Christian; Gauly, Adelheid; Atiye, Saynab; Stauss-Grabo, Manuela; Giefer, Mareike (2022). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications&quot;</a>. <em>Therapeutic Apheresis and Dialysis</em>. <strong>26</strong> (1): 229–241. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2F1744-9987.13663" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/1744-9987.13663</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9291474</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/33914397" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33914397</a>.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hirano R, Namazuda K, Hirata N (April 2021). &quot;Double filtration plasmapheresis: Review of current clinical applications&quot;. <em>Ther Apher Dial</em>. <strong>25</strong> (2): 145–151. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2F1744-9987.13548" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/1744-9987.13548</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32558286" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32558286</a>.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lambert C, Gericke M, Smith R, Hermans C (2011). &quot;Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+&quot;. <em>J Clin Apher</em>. <strong>26</strong> (1): 17–22. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fjca.20271" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/jca.20271</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21312255" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21312255</a>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://worldwide.espacenet.com/textdoc?DB=EPODOC&amp;IDX=US7108672" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">US patent 7108672</a>, &quot;Extracorporeal blood processing methods and apparatus&quot;</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.transfusions.org/p/apheresis.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Apheresis&quot;</a>. Retrieved 2022-10-24.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vurro F, Merolle L, Marraccini C, Parisi M, Canovi L, Erta B, Santachiara A, Bonvicini L, Giorgi Rossi P, Baricchi R, Pertinhez TA (June 2019). &quot;Quantitative assessment of the anticoagulant in plasma units collected by plasmapheresis&quot;. <em>Transfusion</em>. <strong>59</strong> (6): 2113–20. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Ftrf.15244" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/trf.15244</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30875439" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30875439</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://www.cc.nih.gov/dtm/dtm_double_red_cell.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">dtm double red cell</a> <a href="https://web.archive.org/web/20070705090407/http://www.cc.nih.gov/dtm/dtm_double_red_cell.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> July 5, 2007, at the <span class="inline text-[1em] leading-7">Wayback Machine</span></span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lodermeier MA, Byrne KM, Flegel WA (October 2017). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656404" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Red blood cell sedimentation of Apheresis Granulocytes&quot;</a>. <em>Transfusion</em>. <strong>57</strong> (10): 2551–2. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Ftrf.14251" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/trf.14251</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656404" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5656404</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28815621" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28815621</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Yamanaka I, Yamauchi T, Henzan T, Sakoda T, Miyamoto K, Mishima H, Ono H, Koga Y, Nakashima Y, Kato K, Miyamoto T, Mizuno S, Ogawa Y, Ohga S, Akashi K, Maeda T, Kunisaki Y (October 2021). &quot;Optimization of lymphapheresis for manufacturing autologous CAR-T cells&quot;. <em>Int J Hematol</em>. <strong>114</strong> (4): 449–458. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs12185-021-03191-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s12185-021-03191-x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34275066" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34275066</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vrielink H, Neyrinck MM (April 2023). &quot;Basics of apheresis and equipment&quot;. <em>Transfus Apher Sci</em>. <strong>62</strong> (2): 103671. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.transci.2023.103671" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.transci.2023.103671</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/36870905" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">36870905</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Strauss, Ronald G. (1984). &quot;Apheresis donor safety – changes in humoral and cellular immunity&quot;. <em>Journal of Clinical Apheresis</em>. <strong>2</strong> (1): 68–80. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fjca.2920020112" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/jca.2920020112</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/6536660" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6536660</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:25890912" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25890912</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20090117033956/https://www.fda.gov/cber/recalls/baxaphe013105.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Recall of Amicus Apheresis Kits, Baxter Healthcare Corporation&quot;</a>. <em><span class="inline text-[1em] leading-7">Food and Drug Administration</span></em>. Archived from <a href="https://www.fda.gov/CbER/recalls/baxaphe013105.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2009-01-17. Retrieved 2008-12-20. &quot;Recall of Amicus Apheresis Kits, Baxter Healthcare Corporation&quot;, US FDA, Jan 31 2005</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20090709195045/http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm053390.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Recall of CS3000 Apheresis Kits&quot;</a>. <em><span class="inline text-[1em] leading-7">Food and Drug Administration</span></em>. June 21, 2007. Archived from <a href="https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm053390.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on July 9, 2009.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Boulton F (2007). &quot;The 13% rule. Comments&quot;. <em>Transfusion Today</em>. <strong>71</strong> : 7–9.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Larsson L, Sandgren P, Ohlsson S, Derving J, Friis-Christensen T, Daggert F, Frizi N, Reichenberg S, Chatellier S, Diedrich B, Antovic J, Larsson S, Uhlin M (January 2021). <a href="https://doi.org/10.1111%2Fvox.12982" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Non-phthalate plasticizer DEHT preserves adequate blood component quality during storage in PVC blood bags&quot;</a>. <em>Vox Sang</em>. <strong>116</strong> (1): 60–70. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fvox.12982" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/vox.12982</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32918773" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32918773</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Koch, Holger M.; Bolt, Hermann M.; Preuss, Ralf; Eckstein, Reinhold; Weisbach, Volker; Angerer, Jürgen (2005). &quot;Intravenous exposure to di(2-ethylhexyl)phthalate (DEHP): Metabolites of DEHP in urine after a voluntary platelet donation&quot;. <em>Archives of Toxicology</em>. <strong>79</strong> (12): 689–93. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2005ArTox..79..689K" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2005ArTox..79..689K</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs00204-005-0004-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s00204-005-0004-x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16059725" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16059725</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:743051" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">743051</a>.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Buchta, Christoph; Bittner, Claudia; Höcker, Paul; Macher, Maria; Schmid, Rainer; Seger, Christoph; Dettke, Markus (2003). &quot;Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis&quot;. <em>Transfusion</em>. <strong>43</strong> (8): 1115–20. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1046%2Fj.1537-2995.2003.00479.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1046/j.1537-2995.2003.00479.x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12869118" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12869118</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:34539126" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34539126</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Koch, Holger M.; Angerer, Jürgen; Drexler, Hans; Eckstein, Reinhold; Weisbach, Volker (2005). &quot;Di(2-ethylhexyl)phthalate (DEHP) exposure of voluntary plasma and platelet donors&quot;. <em>International Journal of Hygiene and Environmental Health</em>. <strong>208</strong> (6): 489–98. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2005IJHEH.208..489K" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2005IJHEH.208..489K</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ijheh.2005.07.001" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ijheh.2005.07.001</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16325559" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16325559</a>.</span></div></li><li id="https://ushospitalproducts.baxter.com/transitioning-dehp-free-future" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ushospitalproducts.baxter.com/transitioning-dehp-free-future" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ushospitalproducts.baxter.com/transitioning-dehp-free-future</a></span></div></li><li id="https://familyheart.org/fh-treatments/lipoprotein-apheresis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://familyheart.org/fh-treatments/lipoprotein-apheresis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://familyheart.org/fh-treatments/lipoprotein-apheresis</a></span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Connelly-Smith, Laura; Alquist, Caroline; Aqui, Nicole; Hofmann, Jan; Klingel, Reinhard; et al. (2023). &quot;Guidelines on the Use of Therapeutic Apheresis in Clinical Practice — Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue&quot;. <em>The Journal of Clinical Apheresis</em>. <strong>38</strong> (2): 77–278. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fjca.22043" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/jca.22043</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/37017433" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">37017433</a>.</span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Apheresis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz" id="_R_" async=""></script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Apheresis\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Apheresis\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Apheresis\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T75ff,"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"# Apheresis\n\n**Apheresis** (from Ancient Greek ἀφαίρεσις _aphairesis_, \"a taking away\") is a medical technology in which the blood of a person is passed through an apparatus that separates one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy.\n\nOne of the uses of apheresis is for collecting hematopoietic stem cells.[1]\n## Method\n\nDepending on the substance that is being removed, different processes are employed in apheresis. If separation by density is required, centrifugation is the most common method. Other methods involve absorption onto beads coated with an absorbent material[2] and filtration.[3]\n\nThe centrifugation method can be divided into two basic categories:[4]\n\n### Continuous flow centrifugation\n\nContinuous flow centrifugation (CFC) historically required two venipunctures, as \"continuous\" means the blood is collected, spun, and returned simultaneously. Newer systems can operate with a single venipuncture by collecting blood in a vessel and alternating between drawing and returning it through the same needle, while the centrifuge continuously processes the blood held in the vessel.[5] The main advantage of this system is the low extracorporeal volume used in the procedure, which may be advantageous in the elderly and for children. \n\n### Intermittent flow centrifugation\n\nIntermittent flow centrifugation (IFC) works in cycles, taking blood, spinning/processing it and then giving back the unused parts to the donor in a bolus. The main advantage is a single venipuncture site. It does require a larger extracorporeal volume and takes significantly longer to perform the procedure via IFC. As a result, it is less commonly used for therapeutic purposes and is more frequently found in Donation Center settings.[6] To stop the blood from coagulating, an anticoagulant is automatically mixed with the blood as it is pumped from the body into the apheresis machine.[7]\n\n### Centrifugation variables\n\nThe centrifugation process itself has four variables that can be controlled to selectively remove desired components. The first is spin speed and bowl diameter, the second is \"sit time\" in the centrifuge, the third is solutes added, and the fourth is not as easily controllable: plasma volume and cellular content of the donor. The result in most cases is the classic sedimented blood sample with the red blood cells at the bottom, the buffy coat of platelets and white blood cells (lymphocytes, granulocytes, monocytes) in the middle and the plasma on top.\n# Apheresis\n\n## Types\n\nThere are numerous types of apheresis. \n\n### Donation\n\nBlood taken from a healthy donor can be separated into its parts during [blood donation](Blood_donation \"Blood donation\"), where the needed component is collected and the unharvested components are returned to the donor. [Fluid replacement](Fluid_replacement \"Fluid replacement\") is usually not needed in this type of collection. In many countries, apheresis donors can donate platelets more often than those donating whole blood. There are several categories of component collections: \n\n* [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") – [blood plasma](Blood_plasma \"Blood plasma\"). Plasmapheresis is useful in collecting FFP (fresh frozen plasma) of a particular ABO group. Commercial uses aside from FFP for this procedure include immunoglobulin products, plasma derivatives, and the collection of rare WBC and RBC antibodies.\n\n* [Erythrocytapheresis](Erythrocytapheresis \"Erythrocytapheresis\") – [red blood cells](Red_blood_cells \"Red blood cells\"). Erythrocytapheresis is the separation of [erythrocytes](Erythrocytes \"Erythrocytes\") from whole blood. It is most commonly accomplished using the method of centrifugal sedimentation. The automated red blood cell collection procedure for donating erythrocytes is referred to as 'Double Reds' or 'Double Red Cell Apheresis.'[9]\n\n* [Plateletpheresis](Plateletpheresis \"Plateletpheresis\") (thrombapheresis, thrombocytapheresis) – [blood platelets](Platelet \"Platelet\"). Plateletpheresis is the collection of platelets by apheresis while returning the RBCs, WBCs, and component plasma. The yield is normally the equivalent of between six and ten random platelet concentrates. Quality control demands the platelets from apheresis be equal to or greater than 3.0 × 1011 in number and have a pH of equal to or greater than 6.2 in 90% of the products tested and must be used within five days.\n\n* [Leukapheresis](Leukapheresis \"Leukapheresis\") – [leukocytes](Leukocytes \"Leukocytes\") (white blood cells). Leukopheresis is the removal of [PMNs](Granulocyte \"Granulocyte\"), basophils, eosinophils for transfusion into patients whose PMNs are ineffective or where traditional therapy has failed. There is limited data to suggest the benefit of [granulocyte transfusion](Granulocyte_transfusion \"Granulocyte transfusion\"). The complications of this procedure are the difficulty in collection and short shelf life (24 hours at 20 to 24 °C). Since the \"buffy coat\" layer sits directly atop the RBC layer, HES, a sedimenting agent, is employed to improve yield while minimizing RBC collection. Quality control demands the resultant concentrate be 1.0 × 1010 granulocytes in 75% of the units tested and that the product be irradiated to avoid graft-versus-host disease (inactivate lymphocytes). Irradiation does not affect PMN function. Since there is usually a small amount of RBCs collected, ABO compatibility should be employed when feasible.[10]\n\n* Stem cell harvesting – [hematopoietic stem cells](Hematopoietic_stem_cells \"Hematopoietic stem cells\"). Circulating peripheral blood stem cells (PBSCs) are harvested to use in [peripheral stem cell transplantation](Peripheral_stem_cell_transplantation \"Peripheral stem cell transplantation\") following administration of a mobilizing agent, such as granulocyte colony stimulating factor (G-CSF).\n\n* Lymphapheresis – [lymphocytes](Lymphocytes \"Lymphocytes\"). Lymphocytes are harvested to use in manufacture of [CAR T cell](CAR_T_cell \"CAR T cell\") products for T-cell-based immunotherapies.[11]\n\n#### Donor safety\n\n* Single use kits – Apheresis is done using single-use kits, so there is no risk of infection from blood-contaminated tubing or centrifuge. Blood does not contact the device and during the separation, blood does not exit the kit.[8]\n\n* Reinfusion – At the end of the procedure, the remaining blood in the kit is given back to the donor with a process called 'reinfusion'.\n\n* Immune system effects – \"the immediate decreases in blood lymphocyte counts and serum immunoglobulin concentrations are of slight to moderate degree and are without known adverse effects. Less information is available regarding long-term alterations of the immune system\".[12]\n\n##### Kit problems\n\nTwo apheresis kit recalls were: \n\n* Baxter Healthcare Corporation (2005), in which \"pinhole leaks were observed at the two-omega end of the umbilicus (multilumen tubing), causing a blood leak.\"[13]\n\n* Fenwal Incorporated (2007), in which there were \"two instances where the [anticoagulant citrate dextrose](Acid-citrate-dextrose \"Acid-citrate-dextrose\") (ACD) and saline lines were reversed in the assembly process. The reversed line connections may not be visually apparent in the monitor box, and could result in excessive ACD infusion and severe injury, including death, to the donor.\"[14]\n\n##### Donor selection\n\nPeople who do not use a drug that may prevent blood donation, who do not have the risk of the carrier of a disease, and who have suitable vascular structure may be apheresis donors. For apheresis platelet donation the donor's pre platelet count should be above 150 x 10^9/L. For apheresis plasma donation, the donor's total protein level should be greater than 60 g/L. For double red cell apheresis, donors of either gender require a minimum hemoglobin level of 14.0 g/dl.[15]\n\n##### Plasticizer exposure\n\nApheresis uses plastics and tubing, which come into contact with the blood. The plastics are made of [PVC](PVC \"PVC\") in addition to additives such as a [plasticizer](Plasticizer \"Plasticizer\"), often [DEHP](DEHP \"DEHP\"). DEHP leaches from the plastic into the blood, and people have begun to study the possible effects of this leached DEHP on donors as well as transfusion recipients.[16]\n\n* \"current risk or preventive limit values for DEHP such as the RfD of the US EPA (20 μg/kg/day) and the TDI of the European Union (20–48 μg/kg/day) can be exceeded on the day of the plateletpheresis. ... Especially women in their reproductive age need to be protected from DEHP exposures exceeding the above mentioned preventive limit values.\"[17]\n\n* \"Commercial plateletpheresis disposables release considerable amounts of DEHP during the apheresis procedure, but the total dose of DEHP retained by the donor is within the normal range of DEHP exposure of the general population.\"[18]\n\n* \"Mean DEHP doses for both plateletpheresis techniques (18.1 and 32.3 μg/kg/day) were close to or exceeded the reference dose (RfD) of the US EPA and tolerable daily intake (TDI) value of the EU on the day of the apheresis. Therefore, margins of safety might be insufficient to protect especially young men and women in their reproductive age from effects on reproductivity. At present, discontinuous-flow devices should be preferred to avert conceivable health risks from plateletpheresis donors. Strategies to avoid DEHP exposure of donors during apheresis need to be developed.\"[19]\n\n* As of 2025, manufacturers like Baxter are transitioning to DEHP-free IV bags and tubing due to regulatory bans in states such as California and North Carolina, with full U.S. transition targeted by 2035.[](https://ushospitalproducts.baxter.com/transitioning-dehp-free-future)\n\n### Therapy\n\nThe various apheresis techniques may be used whenever the removed constituent is causing severe symptoms of disease. Generally, apheresis has to be performed fairly often, and is an invasive process. It is therefore only employed if other means to control a particular disease have failed, or the symptoms are of such a nature that waiting for medication to become effective would cause suffering or risk of complications. For autoimmune diseases in which apheresis is effective, it is used not as a standalone treatment, but rather in conjunction with therapies that reduce production of autoantibodies. \n\n* [Plasma exchange](Plasma_exchange \"Plasma exchange\") – removal of the liquid portion of blood to remove harmful substances. The plasma is replaced with a replacement solution.\n\n* [LDL apheresis](LDL_apheresis \"LDL apheresis\") – removal of [low density lipoprotein](Low_density_lipoprotein \"Low density lipoprotein\") in patients with [familial hypercholesterolemia](Familial_hypercholesterolemia \"Familial hypercholesterolemia\").\n\n* [Lipoprotein(a)](Lipoprotein\\(a\\) \"Lipoprotein\\(a\\)\") (Lp(a)) apheresis – removal of elevated lipoprotein(a) in patients with cardiovascular risk.[](https://familyheart.org/fh-treatments/lipoprotein-apheresis)\n\n* [Photopheresis](Photopheresis \"Photopheresis\") – used to treat [graft-versus-host disease](Graft-versus-host_disease \"Graft-versus-host disease\"), [cutaneous T-cell lymphoma](Cutaneous_T-cell_lymphoma \"Cutaneous T-cell lymphoma\"), and [rejection in heart transplantation](Transplant_rejection \"Transplant rejection\").\n\n* Immunoadsorption with Staphylococcal [protein A](Protein_A \"Protein A\")-agarose column – removal of allo- and autoantibodies (in autoimmune diseases, transplant rejection, hemophilia) by directing plasma through protein A-agarose columns. Protein A is a cell wall component produced by several strains of Staphylococcus aureus which binds to the Fc region of IgG.\n\n* [Leukocytapheresis](Leukoreduction \"Leukoreduction\") – removal of malignant white blood cells in people with leukemia and very high white blood cell counts causing symptoms.\n\n* [Erythrocytapheresis](Erythrocytapheresis \"Erythrocytapheresis\") – removal of erythrocytes (red blood cells) in people with [iron overload](Iron_overload \"Iron overload\") as a result of [Hereditary haemochromatosis](Hereditary_haemochromatosis \"Hereditary haemochromatosis\"). This process is also used for [exchange transfusion](Exchange_transfusion \"Exchange transfusion\") in severe malaria, or in sickle cell patients with specific indications such as acute chest syndrome or stroke.\n\n* [Thrombocytapheresis](Thrombocytapheresis \"Thrombocytapheresis\") – removal of platelets in people with symptoms from extreme elevations in platelet count such as those with [essential thrombocythemia](Essential_thrombocythemia \"Essential thrombocythemia\") or [polycythemia vera](Polycythemia_vera \"Polycythemia vera\").\n# Indications\n\n## ASFA categories\n\nIn 2023,[21] the [American Society for Apheresis](American_Society_for_Apheresis \"American Society for Apheresis\") published the 9th Special Edition of [evidence based guidelines](Evidence-based_medicine \"Evidence-based medicine\") for the practice of Apheresis Medicine. These guidelines are based upon a systematic review of available scientific literature. Clinical utility for a given disease is denoted by assignment of an **ASFA Category** (I – IV). The quality and strength of evidence are denoted by standard [GRADE](Evidence-based_medicine#GRADE_working_group \"Evidence-based medicine\") recommendations. ASFA Categories are defined as follows: \n\n* **Category I** for disorders where therapeutic apheresis is accepted as a first line treatment,\n* **Category II** for disorders where therapeutic apheresis is accepted as a second-line treatment,\n* **Category III** for disorders where the optimal role of therapeutic apheresis is not clearly established and\n* **Category IV** for disorders where therapeutic apheresis is considered ineffective or harmful.\n\n## Diseases and disorders\n\nOnly diseases (or mentioned special conditions thereof) with ASFA category I or II are displayed in **bold** , with category I being _underlined_ in addition. \n\n| Disease | Special condition | Apheresis type | Category |\n|---------|-------------------|----------------|----------|\n| [ABO-incompatible](ABO-incompatible_transplantation \"ABO-incompatible transplantation\") [hematopoietic stem cell transplantation](Hematopoietic_stem_cell_transplantation \"Hematopoietic stem cell transplantation\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n| [ABO-incompatible](ABO-incompatible_transplantation \"ABO-incompatible transplantation\") solid [organ transplantation](Organ_transplantation \"Organ transplantation\") | **Kidney** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n|  | **Heart ( \u003c40 months of age)** |  | II |\n|  | Liver ([perioperative](Perioperative \"Perioperative\")) |  | III |\n| [Acute disseminated encephalomyelitis](Acute_disseminated_encephalomyelitis \"Acute disseminated encephalomyelitis\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n| [_Acute inflammatory demyelinating polyneuropathy_](Acute_inflammatory_demyelinating_polyneuropathy \"Acute inflammatory demyelinating polyneuropathy\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n| [Acute liver failure](Acute_liver_failure \"Acute liver failure\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Age-related macular degeneration](Age-related_macular_degeneration \"Age-related macular degeneration\") (AMD) | Dry AMD | [Rheopheresis](Rheopheresis \"Rheopheresis\") | III |\n| Systemic [amyloidosis](Amyloidosis \"Amyloidosis\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n| [Amyotrophic lateral sclerosis](Amyotrophic_lateral_sclerosis \"Amyotrophic lateral sclerosis\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n| [Anti-neutrophil cytoplasmic antibody](Anti-neutrophil_cytoplasmic_antibody \"Anti-neutrophil cytoplasmic antibody\")-associated [rapidly progressive glomerulonephritis](Rapidly_progressive_glomerulonephritis \"Rapidly progressive glomerulonephritis\") | Dialysis dependence | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n|  | Diffuse alveolar [hemorrhage](Hemorrhage \"Hemorrhage\") (DAH) |  | III |\n|  | Dialysis independence |  | III |\n| [Goodpasture syndrome](Goodpasture_syndrome \"Goodpasture syndrome\") | **_Dialysis independence_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n|  | **_Diffuse alveolar hemorrhage (DAH)_** |  | _I_ |\n|  | Dialysis dependence and no DAH |  | III |\n| [Aplastic anemia](Aplastic_anemia \"Aplastic anemia\") or [pure red cell aplasia](Pure_red_cell_aplasia \"Pure red cell aplasia\") | [Aplastic anemia](Aplastic_anemia \"Aplastic anemia\") | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n|  | **[Pure red cell aplasia](Pure_red_cell_aplasia \"Pure red cell aplasia\")** |  | II |\n| [Autoimmune hemolytic anemia](Autoimmune_hemolytic_anemia \"Autoimmune hemolytic anemia\") | [Warm antibody autoimmune hemolytic anemia](Warm_antibody_autoimmune_hemolytic_anemia \"Warm antibody autoimmune hemolytic anemia\") | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n|  | **[Cold agglutinin disease](Cold_agglutinin_disease \"Cold agglutinin disease\"), life-threatening** |  | II |\n| [Babesiosis](Babesiosis \"Babesiosis\") | **_Severe_** | [Erythrocytapheresis](Erythrocytapheresis \"Erythrocytapheresis\") | _I_ |\n|  | **High-risk population** |  | II |\n| [Burn](Burn \"Burn\") with [circulatory shock](Shock_\\(circulatory\\) \"Shock \\(circulatory\\)\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n| [Heart transplant](Heart_transplant \"Heart transplant\") with allograft  | **_Prophylaxis of rejection_** | [Photopheresis](Photopheresis \"Photopheresis\") | _I_ |\n|  | **Treatment of rejection** |  | II |\n|  | **_Treatment of antibody-mediated rejection_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n| [_Catastrophic antiphospholipid syndrome_](Catastrophic_antiphospholipid_syndrome \"Catastrophic antiphospholipid syndrome\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n| [Rasmussen's encephalitis](Rasmussen's_encephalitis \"Rasmussen's encephalitis\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") or [immunoadsorption](Immunoadsorption \"Immunoadsorption\") | II |\n| [_Chronic inflammatory demyelinating polyneuropathy_](Chronic_inflammatory_demyelinating_polyneuropathy \"Chronic inflammatory demyelinating polyneuropathy\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n| [Coagulation factor](Coagulation_factor \"Coagulation factor\") inhibitors |  | [Immunoadsorption](Immunoadsorption \"Immunoadsorption\") | III |\n|  |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Cryoglobulinemia](Cryoglobulinemia \"Cryoglobulinemia\") | **_Severe/symptomatic_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n|  | **Secondary to[Hepatitis C](Hepatitis_C \"Hepatitis C\")** | [Immunoadsorption](Immunoadsorption \"Immunoadsorption\") | II |\n| [Cutaneous T cell lymphoma](Cutaneous_T_cell_lymphoma \"Cutaneous T cell lymphoma\"): [mycosis fungoides](Mycosis_fungoides \"Mycosis fungoides\") or [Sézary disease](S%C3%A9zary_disease \"Sézary disease\") | **_Erythrodermic_** | [Photopheresis](Photopheresis \"Photopheresis\") | _I_ |\n|  | Non-erythrodermic |  | III |\n| [Dermatomyositis](Dermatomyositis \"Dermatomyositis\") or [polymyositis](Polymyositis \"Polymyositis\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n|  |  | [Leukapheresis](Leukapheresis \"Leukapheresis\") | IV |\n| [Dilated cardiomyopathy](Dilated_cardiomyopathy \"Dilated cardiomyopathy\") | [NYHA class](New_York_Heart_Association_Functional_Classification \"New York Heart Association Functional Classification\") II-IV | [Immunoadsorption](Immunoadsorption \"Immunoadsorption\") or [plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Familial hypercholesterolemia](Familial_hypercholesterolemia \"Familial hypercholesterolemia\") | **_Homozygotes_** | [LDL apheresis](LDL_apheresis \"LDL apheresis\") | _I_ |\n|  | **Heterozygotes** |  | II |\n|  | **Homozygotes with small blood volume** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n| [Focal segmental glomerulosclerosis](Focal_segmental_glomerulosclerosis \"Focal segmental glomerulosclerosis\") | **_Recurrent_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n| [Graft-versus-host disease](Graft-versus-host_disease \"Graft-versus-host disease\") | **Skin** | [Photopheresis](Photopheresis \"Photopheresis\") | II |\n|  | Non-skin |  | II |\n| [Hemolytic disease of the fetus and newborn](Hemolytic_disease_of_the_fetus_and_newborn \"Hemolytic disease of the fetus and newborn\") | **Before intrauterine transfusion availability** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Hereditary haemochromatosis](Hereditary_haemochromatosis \"Hereditary haemochromatosis\") |  | [Erythrocytapheresis](Erythrocytapheresis \"Erythrocytapheresis\") | III |\n| [Hemolytic–uremic syndrome](Hemolytic%E2%80%93uremic_syndrome \"Hemolytic–uremic syndrome\") (HUS)  | **Atypical HUS due to mutations in complement factor genes** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n|  | **_Atypical HUS due to[factor H](Factor_H \"Factor H\") autoantibodies_** |  | _I_ |\n|  | Typical HUS, or diarrhea-associated HUS |  | III |\n| [Leukocytosis](Leukocytosis \"Leukocytosis\") | **_[Leukostasis](Leukostasis \"Leukostasis\")_** | [Leukapheresis](Leukapheresis \"Leukapheresis\") | III |\n|  | Prophylaxis of leukostasis |  | III |\n| [Hyperviscosity](Hyperviscosity \"Hyperviscosity\") in [monoclonal gammopathy](Monoclonal_gammopathy \"Monoclonal gammopathy\") | **_Treatment of symptoms_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n|  | **_Prophylaxis in[rituximab](Rituximab \"Rituximab\")_** |  | II |\n| Immune thrombocytopenic purpura |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n| [Immune complex](Immune_complex \"Immune complex\")-type of [rapidly progressive glomerulonephritis](Rapidly_progressive_glomerulonephritis \"Rapidly progressive glomerulonephritis\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Inclusion body myositis](Inclusion_body_myositis \"Inclusion body myositis\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") or [leukapheresis](Leukapheresis \"Leukapheresis\") | IV |\n| [Inflammatory bowel disease](Inflammatory_bowel_disease \"Inflammatory bowel disease\") |  | [Leukapheresis](Leukapheresis \"Leukapheresis\") | II |\n| [Kidney transplantation](Kidney_transplantation \"Kidney transplantation\") | **_Antibody-mediated rejection_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n|  | **_Desensitization in living donor in positive crossmatch due to donor specific HLA antibody_** |  | _I_ |\n|  | High [PRA](Panel-reactive_antibody \"Panel-reactive antibody\") and cadaveric donor |  | III |\n| [Lambert–Eaton myasthenic syndrome](Lambert%E2%80%93Eaton_myasthenic_syndrome \"Lambert–Eaton myasthenic syndrome\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n| [Lung transplantation](Lung_transplantation \"Lung transplantation\") | **Allograft rejection** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n| [Malaria](Malaria \"Malaria\") | **Severe** | [Erythrocytapheresis](Erythrocytapheresis \"Erythrocytapheresis\") | II |\n| [Multiple sclerosis](Multiple_sclerosis \"Multiple sclerosis\") | **Acute[inflammatory demyelinating diseases of the central nervous system](Inflammatory_demyelinating_diseases_of_the_central_nervous_system \"Inflammatory demyelinating diseases of the central nervous system\"), unresponsive to steroids** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n|  | Chronic progressive |  | III |\n| [Myasthenia gravis](Myasthenia_gravis \"Myasthenia gravis\") | **_Moderate to severe_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n|  | **_Pre-[thymectomy](Thymectomy \"Thymectomy\")_** |  | _I_ |\n| [Myeloma cast nephropathy](Myeloma_cast_nephropathy \"Myeloma cast nephropathy\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n| [Nephrogenic systemic fibrosis](Nephrogenic_systemic_fibrosis \"Nephrogenic systemic fibrosis\") |  | [Photopheresis](Photopheresis \"Photopheresis\") or [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Neuromyelitis optica](Neuromyelitis_optica \"Neuromyelitis optica\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n| [Venoms](Venom \"Venom\"), [poisoning](Poisoning \"Poisoning\") and [overdose](Overdose \"Overdose\") | **[Mushroom poisoning](Mushroom_poisoning \"Mushroom poisoning\")** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n|  | Other |  | III |\n| [Paraneoplastic syndrome](Paraneoplastic_syndrome \"Paraneoplastic syndrome\") | Neurologic | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") or [immunoadsorption](Immunoadsorption \"Immunoadsorption\") | III |\n| [Pancreatitis](Pancreatitis \"Pancreatitis\") | Secondary to [hypertriglyceridemia](Hypertriglyceridemia \"Hypertriglyceridemia\") | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Polyneuropathy](Polyneuropathy \"Polyneuropathy\") due to [monoclonal gammopathy](Monoclonal_gammopathy \"Monoclonal gammopathy\") | **_IgG, IgA or IgM_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n|  | [Multiple myeloma](Multiple_myeloma \"Multiple myeloma\") |  | III |\n|  | IgG/IgA or IgM | [Immunoadsorption](Immunoadsorption \"Immunoadsorption\") | III |\n| _[PANDAS](PANDAS \"PANDAS\") and [Sydenham's chorea](Sydenham's_chorea \"Sydenham's chorea\")_ |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n| [Pemphigus vulgaris](Pemphigus_vulgaris \"Pemphigus vulgaris\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n|  |  | [Photopheresis](Photopheresis \"Photopheresis\") | III |\n| [Refsum disease](Refsum_disease \"Refsum disease\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n| [Polycythemia vera](Polycythemia_vera \"Polycythemia vera\") or [erythrocytosis](Erythrocytosis \"Erythrocytosis\") |  | [Erythrocytapheresis](Erythrocytapheresis \"Erythrocytapheresis\") | III |\n| [POEMS syndrome](POEMS_syndrome \"POEMS syndrome\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n| [Post-transfusion purpura](Post-transfusion_purpura \"Post-transfusion purpura\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Psoriasis](Psoriasis \"Psoriasis\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n| [Rheumatoid arthritis](Rheumatoid_arthritis \"Rheumatoid arthritis\") | **Refractory** | [Immunoadsorption](Immunoadsorption \"Immunoadsorption\") | II |\n| [Schizophrenia](Schizophrenia \"Schizophrenia\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n| [Systemic scleroderma](Systemic_scleroderma \"Systemic scleroderma\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n|  |  | [Photopheresis](Photopheresis \"Photopheresis\") | IV |\n| [Sepsis](Sepsis \"Sepsis\") with [multi-organ failure](Multi-organ_failure \"Multi-organ failure\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Sickle cell disease](Sickle_cell_disease \"Sickle cell disease\") | **_Acute[stroke](Stroke \"Stroke\")_** | [Erythrocytapheresis](Erythrocytapheresis \"Erythrocytapheresis\") | _I_ |\n|  | **[Acute chest syndrome](Acute_chest_syndrome \"Acute chest syndrome\")** |  | II |\n|  | **Prophylaxis of stroke or transfusional[iron overload](Iron_overload \"Iron overload\")** |  | II |\n|  | [Multi-organ failure](Multi-organ_failure \"Multi-organ failure\") |  | III |\n| [Stiff-person syndrome](Stiff-person_syndrome \"Stiff-person syndrome\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | IV |\n| [Systemic lupus erythematosus](Systemic_lupus_erythematosus \"Systemic lupus erythematosus\") | **Severe, such as[cerebritis](Cerebritis \"Cerebritis\") or [diffuse alveolar hemorrhage](Diffuse_alveolar_hemorrhage \"Diffuse alveolar hemorrhage\")** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | II |\n|  | [Nephritis](Nephritis \"Nephritis\") |  | IV |\n| [Thrombocytosis](Thrombocytosis \"Thrombocytosis\") | **Symptomatic** | [Plateletpheresis](Plateletpheresis \"Plateletpheresis\") | II |\n|  | Prophylactic |  | III |\n| [Thrombotic microangiopathy](Thrombotic_microangiopathy \"Thrombotic microangiopathy\"), drug-associated  | **_[Ticlopidine](Ticlopidine \"Ticlopidine\")_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n|  | [Cyclosporine](Cyclosporine \"Cyclosporine\")\u003cbr\u003e[Tacrolimus](Tacrolimus \"Tacrolimus\")\u003cbr\u003e[Clopidogrel](Clopidogrel \"Clopidogrel\") |  | III |\n|  | [Gemcitabine](Gemcitabine \"Gemcitabine\")\u003cbr\u003e[Quinine](Quinine \"Quinine\") |  | IV |\n| [Thrombotic microangiopathy](Thrombotic_microangiopathy \"Thrombotic microangiopathy\"), [hematopoietic stem cell transplantation](Hematopoietic_stem_cell_transplantation \"Hematopoietic stem cell transplantation\")-related  |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [_Thrombotic thrombocytopenic purpura_](Thrombotic_thrombocytopenic_purpura \"Thrombotic thrombocytopenic purpura\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n| [Thyroid storm](Thyroid_storm \"Thyroid storm\") |  | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | III |\n| [Wilson's disease](Wilson's_disease \"Wilson's disease\") | **_Fulminant hepatic failure with hemolysis_** | [Plasmapheresis](Plasmapheresis \"Plasmapheresis\") | _I_ |\n# Fluid replacement during apheresis\n\nWhen an apheresis system is used for therapy, the system removes typically 1 to 1.5 times the patient's plasma volume (approximately 40-60 mL/kg body weight).[21] That fluid must be replaced to maintain intravascular volume. The choice of replacement fluid varies by institution and indication. Crystalloids like normal saline are sometimes used but do not maintain oncotic pressure and are not routinely recommended as the sole replacement fluid due to risk of hypotension. Human serum albumin is commonly used but is costly. Routine use of fresh frozen plasma (FFP) is generally not appropriate because of risks including citrate toxicity (from the anticoagulant), ABO incompatibility, infection, and allergic reactions. However, FFP should be used in cases of thrombotic thrombocytopenic purpura or patients at high risk of bleeding.[21]"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761882148376,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** Katherine, Abel; American Academy of Professional Coders (2013). _Official CPC Certification Study Guide_. Delmar Cengage Learning. p. 128\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-285-42799-7. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [1073648099](https://search.worldcat.org/oclc/1073648099).\",\"description\":\"1. **^** Katherine, Abel; American Academy of Professional Coders (2013). _Official CPC Certification Study Guide_. Delmar Cengage Learning. p. 128\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-285-42799-7. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [1073648099](https://search.worldcat.org/oclc/1073648099).\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"** Fuchs, Kornelius; Rummler, Silke; Ries, Wolfgang; Helmschrott, Matthias; Selbach, Jochen; Ernst, Friedlinde; Morath, Christian; Gauly, Adelheid; Atiye, Saynab; Stauss-Grabo, Manuela; Giefer, Mareike (2022). [\\\"Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474). _Therapeutic Apheresis and Dialysis_. **26** (1): 229–241\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/1744-9987.13663](https://doi.org/10.1111%2F1744-9987.13663). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [9291474](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33914397](https://pubmed.ncbi.nlm.nih.gov/33914397).\",\"description\":\"2. **^** Fuchs, Kornelius; Rummler, Silke; Ries, Wolfgang; Helmschrott, Matthias; Selbach, Jochen; Ernst, Friedlinde; Morath, Christian; Gauly, Adelheid; Atiye, Saynab; Stauss-Grabo, Manuela; Giefer, Mareike (2022). [\\\"Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474). _Therapeutic Apheresis and Dialysis_. **26** (1): 229–241\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/1744-9987.13663](https://doi.org/10.1111%2F1744-9987.13663). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [9291474](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33914397](https://pubmed.ncbi.nlm.nih.gov/33914397).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** Hirano R, Namazuda K, Hirata N (April 2021). \\\"Double filtration plasmapheresis: Review of current clinical applications\\\". _Ther Apher Dial_. **25** (2): 145–151\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/1744-9987.13548](https://doi.org/10.1111%2F1744-9987.13548). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32558286](https://pubmed.ncbi.nlm.nih.gov/32558286).\",\"description\":\"3. **^** Hirano R, Namazuda K, Hirata N (April 2021). \\\"Double filtration plasmapheresis: Review of current clinical applications\\\". _Ther Apher Dial_. **25** (2): 145–151\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/1744-9987.13548](https://doi.org/10.1111%2F1744-9987.13548). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32558286](https://pubmed.ncbi.nlm.nih.gov/32558286).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** Lambert C, Gericke M, Smith R, Hermans C (2011). \\\"Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+\\\". _J Clin Apher_. **26** (1): 17–22\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/jca.20271](https://doi.org/10.1002%2Fjca.20271). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21312255](https://pubmed.ncbi.nlm.nih.gov/21312255).\",\"description\":\"4. **^** Lambert C, Gericke M, Smith R, Hermans C (2011). \\\"Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+\\\". _J Clin Apher_. **26** (1): 17–22\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/jca.20271](https://doi.org/10.1002%2Fjca.20271). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21312255](https://pubmed.ncbi.nlm.nih.gov/21312255).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** [US patent 7108672](https://worldwide.espacenet.com/textdoc?DB=EPODOC\u0026IDX=US7108672), \\\"Extracorporeal blood processing methods and apparatus\\\"\",\"description\":\"5. **^** [US patent 7108672](https://worldwide.espacenet.com/textdoc?DB=EPODOC\u0026IDX=US7108672), \\\"Extracorporeal blood processing methods and apparatus\\\"\",\"url\":\"https://worldwide.espacenet.com/textdoc?DB=EPODOC\u0026IDX=US7108672\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** [\\\"Apheresis\\\"](https://www.transfusions.org/p/apheresis.html). Retrieved 2022-10-24.\",\"description\":\"6. **^** [\\\"Apheresis\\\"](https://www.transfusions.org/p/apheresis.html). Retrieved 2022-10-24.\",\"url\":\"https://www.transfusions.org/p/apheresis.html\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Vurro F, Merolle L, Marraccini C, Parisi M, Canovi L, Erta B, Santachiara A, Bonvicini L, Giorgi Rossi P, Baricchi R, Pertinhez TA (June 2019). \\\"Quantitative assessment of the anticoagulant in plasma units collected by plasmapheresis\\\". _Transfusion_. **59** (6): 2113–20\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/trf.15244](https://doi.org/10.1111%2Ftrf.15244). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30875439](https://pubmed.ncbi.nlm.nih.gov/30875439).\",\"description\":\"7. **^** Vurro F, Merolle L, Marraccini C, Parisi M, Canovi L, Erta B, Santachiara A, Bonvicini L, Giorgi Rossi P, Baricchi R, Pertinhez TA (June 2019). \\\"Quantitative assessment of the anticoagulant in plasma units collected by plasmapheresis\\\". _Transfusion_. **59** (6): 2113–20\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/trf.15244](https://doi.org/10.1111%2Ftrf.15244). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30875439](https://pubmed.ncbi.nlm.nih.gov/30875439).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"_**a**_ _**b**_ Vrielink H, Neyrinck MM (April 2023). \\\"Basics of apheresis and equipment\\\". _Transfus Apher Sci_. **62** (2): 103671. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.transci.2023.103671](https://doi.org/10.1016%2Fj.transci.2023.103671). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36870905](https://pubmed.ncbi.nlm.nih.gov/36870905).\",\"description\":\"8. ^ _**a**_ _**b**_ Vrielink H, Neyrinck MM (April 2023). \\\"Basics of apheresis and equipment\\\". _Transfus Apher Sci_. **62** (2): 103671. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.transci.2023.103671](https://doi.org/10.1016%2Fj.transci.2023.103671). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36870905](https://pubmed.ncbi.nlm.nih.gov/36870905).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** [dtm double red cell](http://www.cc.nih.gov/dtm/dtm_double_red_cell.htm) [Archived](https://web.archive.org/web/20070705090407/http://www.cc.nih.gov/dtm/dtm_double_red_cell.htm) July 5, 2007, at the [Wayback Machine](Wayback_Machine \\\"Wayback Machine\\\")\",\"description\":\"9. **^** [dtm double red cell](http://www.cc.nih.gov/dtm/dtm_double_red_cell.htm) [Archived](https://web.archive.org/web/20070705090407/http://www.cc.nih.gov/dtm/dtm_double_red_cell.htm) July 5, 2007, at the [Wayback Machine](Wayback_Machine \\\"Wayback Machine\\\")\",\"url\":\"http://www.cc.nih.gov/dtm/dtm_double_red_cell.htm\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Lodermeier MA, Byrne KM, Flegel WA (October 2017). [\\\"Red blood cell sedimentation of Apheresis Granulocytes\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656404). _Transfusion_. **57** (10): 2551–2\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/trf.14251](https://doi.org/10.1111%2Ftrf.14251). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5656404](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656404). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28815621](https://pubmed.ncbi.nlm.nih.gov/28815621).\",\"description\":\"10. **^** Lodermeier MA, Byrne KM, Flegel WA (October 2017). [\\\"Red blood cell sedimentation of Apheresis Granulocytes\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656404). _Transfusion_. **57** (10): 2551–2\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/trf.14251](https://doi.org/10.1111%2Ftrf.14251). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5656404](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656404). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28815621](https://pubmed.ncbi.nlm.nih.gov/28815621).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656404\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Yamanaka I, Yamauchi T, Henzan T, Sakoda T, Miyamoto K, Mishima H, Ono H, Koga Y, Nakashima Y, Kato K, Miyamoto T, Mizuno S, Ogawa Y, Ohga S, Akashi K, Maeda T, Kunisaki Y (October 2021). \\\"Optimization of lymphapheresis for manufacturing autologous CAR-T cells\\\". _Int J Hematol_. **114** (4): 449–458\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s12185-021-03191-x](https://doi.org/10.1007%2Fs12185-021-03191-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34275066](https://pubmed.ncbi.nlm.nih.gov/34275066).\",\"description\":\"11. **^** Yamanaka I, Yamauchi T, Henzan T, Sakoda T, Miyamoto K, Mishima H, Ono H, Koga Y, Nakashima Y, Kato K, Miyamoto T, Mizuno S, Ogawa Y, Ohga S, Akashi K, Maeda T, Kunisaki Y (October 2021). \\\"Optimization of lymphapheresis for manufacturing autologous CAR-T cells\\\". _Int J Hematol_. **114** (4): 449–458\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s12185-021-03191-x](https://doi.org/10.1007%2Fs12185-021-03191-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34275066](https://pubmed.ncbi.nlm.nih.gov/34275066).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** Strauss, Ronald G. (1984). \\\"Apheresis donor safety – changes in humoral and cellular immunity\\\". _Journal of Clinical Apheresis_. **2** (1): 68–80\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/jca.2920020112](https://doi.org/10.1002%2Fjca.2920020112). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [6536660](https://pubmed.ncbi.nlm.nih.gov/6536660). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25890912](https://api.semanticscholar.org/CorpusID:25890912).\",\"description\":\"12. **^** Strauss, Ronald G. (1984). \\\"Apheresis donor safety – changes in humoral and cellular immunity\\\". _Journal of Clinical Apheresis_. **2** (1): 68–80\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/jca.2920020112](https://doi.org/10.1002%2Fjca.2920020112). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [6536660](https://pubmed.ncbi.nlm.nih.gov/6536660). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25890912](https://api.semanticscholar.org/CorpusID:25890912).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** [\\\"Recall of Amicus Apheresis Kits, Baxter Healthcare Corporation\\\"](https://web.archive.org/web/20090117033956/https://www.fda.gov/cber/recalls/baxaphe013105.htm). _[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\")_. Archived from [the original](https://www.fda.gov/CbER/recalls/baxaphe013105.htm) on 2009-01-17. Retrieved 2008-12-20. \\\"Recall of Amicus Apheresis Kits, Baxter Healthcare Corporation\\\", US FDA, Jan 31 2005\",\"description\":\"13. **^** [\\\"Recall of Amicus Apheresis Kits, Baxter Healthcare Corporation\\\"](https://web.archive.org/web/20090117033956/https://www.fda.gov/cber/recalls/baxaphe013105.htm). _[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\")_. Archived from [the original](https://www.fda.gov/CbER/recalls/baxaphe013105.htm) on 2009-01-17. Retrieved 2008-12-20. \\\"Recall of Amicus Apheresis Kits, Baxter Healthcare Corporation\\\", US FDA, Jan 31 2005\",\"url\":\"https://web.archive.org/web/20090117033956/https://www.fda.gov/cber/recalls/baxaphe013105.htm\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** [\\\"Recall of CS3000 Apheresis Kits\\\"](https://web.archive.org/web/20090709195045/http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm053390.htm). _[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\")_. June 21, 2007. Archived from [the original](https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm053390.htm) on July 9, 2009.\",\"description\":\"14. **^** [\\\"Recall of CS3000 Apheresis Kits\\\"](https://web.archive.org/web/20090709195045/http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm053390.htm). _[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\")_. June 21, 2007. Archived from [the original](https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm053390.htm) on July 9, 2009.\",\"url\":\"https://web.archive.org/web/20090709195045/http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm053390.htm\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Boulton F (2007). \\\"The 13% rule. Comments\\\". _Transfusion Today_. **71** : 7–9.\",\"description\":\"15. **^** Boulton F (2007). \\\"The 13% rule. Comments\\\". _Transfusion Today_. **71** : 7–9.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Larsson L, Sandgren P, Ohlsson S, Derving J, Friis-Christensen T, Daggert F, Frizi N, Reichenberg S, Chatellier S, Diedrich B, Antovic J, Larsson S, Uhlin M (January 2021). [\\\"Non-phthalate plasticizer DEHT preserves adequate blood component quality during storage in PVC blood bags\\\"](https://doi.org/10.1111%2Fvox.12982). _Vox Sang_. **116** (1): 60–70\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/vox.12982](https://doi.org/10.1111%2Fvox.12982). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32918773](https://pubmed.ncbi.nlm.nih.gov/32918773).\",\"description\":\"16. **^** Larsson L, Sandgren P, Ohlsson S, Derving J, Friis-Christensen T, Daggert F, Frizi N, Reichenberg S, Chatellier S, Diedrich B, Antovic J, Larsson S, Uhlin M (January 2021). [\\\"Non-phthalate plasticizer DEHT preserves adequate blood component quality during storage in PVC blood bags\\\"](https://doi.org/10.1111%2Fvox.12982). _Vox Sang_. **116** (1): 60–70\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/vox.12982](https://doi.org/10.1111%2Fvox.12982). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32918773](https://pubmed.ncbi.nlm.nih.gov/32918773).\",\"url\":\"https://doi.org/10.1111%2Fvox.12982\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Koch, Holger M.; Bolt, Hermann M.; Preuss, Ralf; Eckstein, Reinhold; Weisbach, Volker; Angerer, Jürgen (2005). \\\"Intravenous exposure to di(2-ethylhexyl)phthalate (DEHP): Metabolites of DEHP in urine after a voluntary platelet donation\\\". _Archives of Toxicology_. **79** (12): 689–93\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2005ArTox..79..689K](https://ui.adsabs.harvard.edu/abs/2005ArTox..79..689K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s00204-005-0004-x](https://doi.org/10.1007%2Fs00204-005-0004-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16059725](https://pubmed.ncbi.nlm.nih.gov/16059725). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [743051](https://api.semanticscholar.org/CorpusID:743051).\",\"description\":\"17. **^** Koch, Holger M.; Bolt, Hermann M.; Preuss, Ralf; Eckstein, Reinhold; Weisbach, Volker; Angerer, Jürgen (2005). \\\"Intravenous exposure to di(2-ethylhexyl)phthalate (DEHP): Metabolites of DEHP in urine after a voluntary platelet donation\\\". _Archives of Toxicology_. **79** (12): 689–93\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2005ArTox..79..689K](https://ui.adsabs.harvard.edu/abs/2005ArTox..79..689K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s00204-005-0004-x](https://doi.org/10.1007%2Fs00204-005-0004-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16059725](https://pubmed.ncbi.nlm.nih.gov/16059725). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [743051](https://api.semanticscholar.org/CorpusID:743051).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Buchta, Christoph; Bittner, Claudia; Höcker, Paul; Macher, Maria; Schmid, Rainer; Seger, Christoph; Dettke, Markus (2003). \\\"Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis\\\". _Transfusion_. **43** (8): 1115–20\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1046/j.1537-2995.2003.00479.x](https://doi.org/10.1046%2Fj.1537-2995.2003.00479.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12869118](https://pubmed.ncbi.nlm.nih.gov/12869118). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [34539126](https://api.semanticscholar.org/CorpusID:34539126).\",\"description\":\"18. **^** Buchta, Christoph; Bittner, Claudia; Höcker, Paul; Macher, Maria; Schmid, Rainer; Seger, Christoph; Dettke, Markus (2003). \\\"Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis\\\". _Transfusion_. **43** (8): 1115–20\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1046/j.1537-2995.2003.00479.x](https://doi.org/10.1046%2Fj.1537-2995.2003.00479.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12869118](https://pubmed.ncbi.nlm.nih.gov/12869118). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [34539126](https://api.semanticscholar.org/CorpusID:34539126).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Koch, Holger M.; Angerer, Jürgen; Drexler, Hans; Eckstein, Reinhold; Weisbach, Volker (2005). \\\"Di(2-ethylhexyl)phthalate (DEHP) exposure of voluntary plasma and platelet donors\\\". _International Journal of Hygiene and Environmental Health_. **208** (6): 489–98\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2005IJHEH.208..489K](https://ui.adsabs.harvard.edu/abs/2005IJHEH.208..489K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijheh.2005.07.001](https://doi.org/10.1016%2Fj.ijheh.2005.07.001). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16325559](https://pubmed.ncbi.nlm.nih.gov/16325559).\",\"description\":\"19. **^** Koch, Holger M.; Angerer, Jürgen; Drexler, Hans; Eckstein, Reinhold; Weisbach, Volker (2005). \\\"Di(2-ethylhexyl)phthalate (DEHP) exposure of voluntary plasma and platelet donors\\\". _International Journal of Hygiene and Environmental Health_. **208** (6): 489–98\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2005IJHEH.208..489K](https://ui.adsabs.harvard.edu/abs/2005IJHEH.208..489K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijheh.2005.07.001](https://doi.org/10.1016%2Fj.ijheh.2005.07.001). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16325559](https://pubmed.ncbi.nlm.nih.gov/16325559).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** [\\\"Lipoprotein (a)\\\"](https://www.cdc.gov/genomics/disease/lipoprotein_a.htm). _[CDC](CDC \\\"CDC\\\") Office of Science (OS), Office of Genomics and Precision Public Health_. [U.S. Department of Health \u0026 Human Services](U.S._Department_of_Health_%26_Human_Services \\\"U.S. Department of Health \u0026 Human Services\\\"). 5 July 2022. Retrieved 14 September 2022.\",\"description\":\"20. **^** [\\\"Lipoprotein (a)\\\"](https://www.cdc.gov/genomics/disease/lipoprotein_a.htm). _[CDC](CDC \\\"CDC\\\") Office of Science (OS), Office of Genomics and Precision Public Health_. [U.S. Department of Health \u0026 Human Services](U.S._Department_of_Health_%26_Human_Services \\\"U.S. Department of Health \u0026 Human Services\\\"). 5 July 2022. Retrieved 14 September 2022.\",\"url\":\"https://www.cdc.gov/genomics/disease/lipoprotein_a.htm\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Connelly-Smith, Laura; Alquist, Caroline; Aqui, Nicole; Hofmann, Jan; Klingel, Reinhard; et al. (2023). \\\"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice — Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue\\\". _The Journal of Clinical Apheresis_. **38** (2): 77–278\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/jca.22043](https://doi.org/10.1002%2Fjca.22043). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [37017433](https://pubmed.ncbi.nlm.nih.gov/37017433).\",\"description\":\"21. **^** Connelly-Smith, Laura; Alquist, Caroline; Aqui, Nicole; Hofmann, Jan; Klingel, Reinhard; et al. (2023). \\\"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice — Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue\\\". _The Journal of Clinical Apheresis_. **38** (2): 77–278\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/jca.22043](https://doi.org/10.1002%2Fjca.22043). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [37017433](https://pubmed.ncbi.nlm.nih.gov/37017433).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"low extracorporeal volume (calculated by volume of the apheresis chamber, the donor's hematocrit, and total blood volume of the donor)\",\"explanation\":\"Extracorporeal volume (ECV) in apheresis is the fixed physical volume of blood in the extracorporeal circuit (e.g., tubing and centrifuge chamber) at any time. It is not calculated using the donor's hematocrit or total blood volume; these factors are used to evaluate procedural safety relative to the patient's total blood volume (e.g., ECV should be \u003c10-15% of TBV for safety). This misstates the mechanism of ECV determination.\",\"fixedText\":\"Revise to: \\\"the low extracorporeal volume used in the procedure, which may be advantageous...\\\" Remove the incorrect calculation parenthetical.\",\"evidenceSource\":\"[web:59] from search: \\\"Extracorporeal volume is defined as the quantity of donor blood remaining outside his body at any given time during the procedure.\\\"\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"The centrifugation process itself has four variables that can be controlled to selectively remove desired components. The first is spin speed and bowl diameter, the second is \\\"sit time\\\" in the centrifuge, the third is solutes added, and the fourth is not as easily controllable: plasma volume and cellular content of the donor. The result in most cases is the classic sedimented blood sample with the RBCs at the bottom, the buffy coat of platelets and WBCs (lymphocytes, granulocytes, monocytes) in the middle and the plasma on top.[8]\",\"explanation\":\"The cited source [8] (Vrielink \u0026 Neyrinck, 2023) discusses basics of apheresis equipment and centrifugal separation based on specific gravity but does not explicitly list or describe these four specific variables (spin speed/bowl diameter, sit time, solutes, donor plasma/cellular content). This creates a mismatch where the source does not support the detailed claim.\",\"fixedText\":\"Remove the citation [8] from this paragraph, as the general separation result is standard knowledge but the specific variables list lacks direct support. Retain the descriptive sentence on sedimentation if verifiable as common knowledge.\",\"evidenceSource\":\"[8] abstract via PubMed: Focuses on general principles and equipment safety, no mention of these variables.\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Lipoprotein(a) (Lp(a) apheresis[20]\",\"explanation\":\"Reference [20] links to a CDC page that is no longer available (404 error) and did not specifically discuss apheresis as a treatment for elevated Lp(a). This leaves the claim unsupported.\",\"fixedText\":\"Replace with a valid source supporting Lp(a) apheresis as a therapeutic use, such as a review article or guidelines.\",\"evidenceSource\":\"Web search confirming Lp(a) apheresis is valid, e.g., [](https://familyheart.org/fh-treatments/lipoprotein-apheresis)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"The Baxter company manufactured blood bags without DEHP, but there was little demand for the product in the marketplace\",\"explanation\":\"This claim is not cited to any reference and appears in a paragraph with cited studies on DEHP exposure. Without a source, it is unverifiable and potentially outdated, as recent developments show increasing demand and regulatory pushes for DEHP-free products.\",\"fixedText\":\"Remove the unsourced claim or add a proper citation if verifiable; note recent regulatory changes for context.\",\"evidenceSource\":\"No matching ref; recent sources show transition to DEHP-free, e.g., [](https://ushospitalproducts.baxter.com/transitioning-dehp-free-future)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; general section]\",\"explanation\":\"The section lacks mention of recent regulatory and industry shifts toward DEHP-free materials in apheresis kits and blood bags, driven by health concerns and laws (e.g., bans in CA and NC effective 2025-2030). This is a knowledge gap on timeliness/currency, as the current date is October 2025, affecting understanding of plasticizer exposure risks.\",\"fixedText\":\"Add a brief note on ongoing transition to non-DEHP alternatives in the Plasticizer exposure subsection, with citation.\",\"evidenceSource\":\"Recent sources, e.g., [](https://www.statnews.com/2024/09/18/dehp-cancer-chemical-california-ban-iv-bags-tubing/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"not more than 10.5 mL/kg body weight\",\"explanation\":\"The stated limit of 10.5 mL/kg is incorrect; standard therapeutic plasma exchange removes 1 to 1.5 times the plasma volume, estimated at 40 mL/kg, resulting in 40-60 mL/kg removed per session. This error misrepresents the procedure's scale and could mislead on fluid management requirements, per ASFA guidelines.\",\"fixedText\":\"Correct to \\\"typically 1 to 1.5 times the patient's plasma volume (approximately 40-60 mL/kg body weight)\\\" and cite ASFA guidelines.\",\"evidenceSource\":\"[21]\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"If a crystalloid like normal saline (NS) is used, the infusion amount should be triple what is removed as the 3:1 ratio of normal saline for plasma is needed to keep up oncotic pressure.\",\"explanation\":\"Normal saline provides no oncotic pressure support, and no standard 3:1 replacement ratio exists for it in plasma exchange; using it alone risks hypotension due to oncotic pressure reduction. Preferred replacement is 1:1 with albumin or mixtures, not pure crystalloid routinely, as per clinical guidelines.\",\"fixedText\":\"Remove the 3:1 ratio claim; state that crystalloids like NS are not routinely recommended as sole replacement due to oncotic pressure concerns, and prefer colloids like albumin at 1:1 volume replacement.\",\"evidenceSource\":\"[21]\"},{\"criticality\":\"Missing\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section lacks reference to authoritative guidelines on replacement fluid choices and volumes, such as the ASFA 2023 recommendations, which specify preferences for albumin in most cases and FFP for specific indications like TTP.\",\"fixedText\":\"Add citations to ASFA guidelines for claims on fluid types, volumes, and indications.\",\"evidenceSource\":\"[21]\"}],\"slug\":\"Apheresis\",\"title\":\"Apheresis\",\"content\":\"$1f\",\"description\":\"Apheresis\\n\\nApheresis (from Ancient Greek ἀφαίρεσις aphairesis, \\\"a taking away\\\") is a medical technology in which the blood of a person is passed through an apparatus that separates one particular...\",\"metadata\":{\"categories\":[\"Aphaeresis\"],\"lastModified\":\"1761552986\",\"contentLength\":\"30207\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"70045\",\"recentViews\":\"70045\",\"dailyAvgViews\":2334.833251953125,\"qualityScore\":1,\"lastViewed\":\"1761882148\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761882148375,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Apheresis\"],\"queryHash\":\"[\\\"page\\\",\\\"Apheresis\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Apheresis\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Apheresis (from Ancient Greek ἀφαίρεσις aphairesis, \\\"a taking away\\\") is a medical technology in which the blood of a person is passed through an apparatus that separates one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy. One of the uses of apheresis is for collecting hematopoietic stem cells.[1] Depending on the substance that is being removed, different processes are employed in apheresis. If separation by density is required,...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Aphaeresis\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Apheresis\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Apheresis\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Apheresis (from Ancient Greek ἀφαίρεσις aphairesis, \\\"a taking away\\\") is a medical technology in which the blood of a person is passed through an apparatus that separates one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy. One of the uses of apheresis is for collecting hematopoietic stem cells.[1] Depending on the substance that is being removed, different processes are employed in apheresis. If separation by density is required,...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Apheresis\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Apheresis\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:12.986Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Apheresis\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Apheresis (from Ancient Greek ἀφαίρεσις aphairesis, \\\"a taking away\\\") is a medical technology in which the blood of a person is passed through an apparatus that separates one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy. One of the uses of apheresis is for collecting hematopoietic stem cells.[1] Depending on the substance that is being removed, different processes are employed in apheresis. If separation by density is required,...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZjJmNDUxMzctNTAzOC00MGNmLWEzYWYtM2QzMTI2MmQ4YTAz">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Apheresis\"}]}]\n"])</script></body></html>